earningsconfidence high
Anteris raises $320M, Q1 cash burn $28.7M; PARADIGM trial enrols in US
Anteris Technologies Global Corp.
2026-Q1 EPS
reported -$0.28
vs consensus -$0.16
▼ miss
(-78.8%)
- Net operating cash outflows of $28.7M for Q1 2026, funding PARADIGM Trial and manufacturing scale-up.
- R&D expenses $17.5M, driven by clinical trial costs, manufacturing process validation, and headcount expansion.
- Completed $320M capital raises in January 2026 to support PARADIGM Trial and global commercialization of DurAVR THV.
- Post quarter-end, US patient enrollment in the PARADIGM Trial commenced; CMS coverage determination supports reimbursement.
- Presented EMBARK Study and EFS data at CRT 2026 and Sydney Valves 2026.
item 2.02item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.